Sermorelin 5MG

£22.99

Purity: ≥ 99%

£22.99

Sermorelin 5MG

Name: Sermorelin 5MG
Brand: Pure Grade Labs
Price: 22.99 GBP
Availability: OutOfStock

£22.99

Purity: ≥ 99%

£22.99

GROWTH HORMONE - GH and IGF-1 pathway research

MUSCLE & FAT - Lean mass and fat loss research

DEEP SLEEP - Nighttime recovery research

AGEING & GH DECLINE - GH drop with age research

Sermorelin is a synthetic 29-amino acid peptide that corresponds to the N-terminal 1-29 fragment of endogenous human growth hormone-releasing hormone (GHRH). The native human GHRH molecule is 44 amino acids long, but in vitro work demonstrated that the first 29 residues retain full biological activity at the GHRH receptor, making sermorelin (also designated GHRH(1-29)NH₂) the shortest fully functional fragment of the parent hormone. It was originally developed by Serono and approved by the FDA in 1997 under the brand name Geref for the diagnosis and treatment of growth hormone deficiency in children. Geref was withdrawn from the US market by the manufacturer in 2008 due to a supply issue with the active ingredient, not for safety or efficacy reasons.

Mechanistically, sermorelin binds the GHRH receptor on somatotroph cells of the anterior pituitary, activates Gαs, and elevates intracellular cAMP, which triggers pulsatile release of endogenous growth hormone (GH). Critically, this differs from exogenous recombinant human GH (rhGH) administration in that sermorelin works through the body's existing feedback architecture: GH and downstream IGF-1 still feed back via somatostatin to limit excessive secretion, and the hypothalamic-pituitary axis remains intact. Sermorelin's terminal half-life is approximately 11-12 minutes, requiring frequent dosing in clinical use. It is now most commonly investigated as a research tool in adult growth hormone insufficiency, age-related GH decline, body composition modelling, and sleep architecture studies.

Mechanism: Selective GHRH receptor agonist on pituitary somatotrophs. Activates adenylate cyclase / cAMP / PKA signalling, triggering physiological pulsatile GH secretion. Downstream, hepatic IGF-1 production rises in response to elevated GH exposure. Negative feedback via somatostatin remains intact.

Research Context: FDA-approved 1997 for pediatric GH deficiency (Geref); withdrawn 2008 due to manufacturing supply. Off-label investigated in adult GH deficiency, age-related somatopause, and HIV-associated lipodystrophy. Compounded sermorelin remains accessible to licensed prescribers in some jurisdictions; closely related GHRH analogue tesamorelin retains approval for HIV lipodystrophy.

Amino Acid Sequence (29 Residues, C-Terminal Amide): H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂

CAS Number: 86168-78-7

Peptide Length: 29 Amino Acids

Half-Life: ~11-12 min

Form: Acetate Salt, Lyophilised

Journal of Clinical Endocrinology & Metabolism RCT / Human: Khorram et al.: Long-term GHRH(1-29) restores GH/IGF-1 axis and increases lean body mass and skin thickness in older adults (n=19)

Metabolism: Clinical and Experimental Controlled Trial / Human: Vittone et al.: Single nightly GHRH(1-29) injections increase nocturnal GH secretion and improve muscle strength in healthy elderly men

BioDrugs (Review) Clinical Review: Prakash & Goa: Sermorelin produces clinically meaningful growth velocity in children with idiopathic GH deficiency

https://pubmed.ncbi.nlm.nih.gov/9141538/

https://pubmed.ncbi.nlm.nih.gov/9005976/

https://pubmed.ncbi.nlm.nih.gov/18031173/

https://pmc.ncbi.nlm.nih.gov/articles/PMC3181657/

https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/

https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/

Every batch of Sermorelin supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Sermorelin is supplied as a lyophilised (freeze-dried) sterile, non-pyrogenic powder as the acetate salt. The peptide is susceptible to enzymatic cleavage at the Arg11-Lys12 and Lys12-Val13 bonds in solution and requires careful handling to preserve integrity. Follow the specifications below.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to minimise condensation and moisture introduction.
Use bacteriostatic water (BAC water) or sterile sodium chloride 0.9% as the reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl until fully dissolved. Do not vortex or shake vigorously, as agitation can disrupt the peptide structure.
Inspect the solution: it should be clear and colourless with no visible particulates. Discard if cloudy, discoloured, or contains particulate matter.
Once reconstituted, store at 2-8°C protected from light. Use within 14-28 days. Do not freeze reconstituted solution

Sermorelin supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. While sermorelin acetate was previously FDA-approved under the brand name Geref for pediatric growth hormone deficiency, that product was withdrawn from the US market in 2008. The research-grade compound supplied here is not equivalent to any approved pharmaceutical product and is not approved for human administration.

This product is not a drug, medicine, or supplement and must not be used as such outside of a licensed clinical or research context.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans for any use of this research compound.
Sermorelin is a prescription-only medicine in jurisdictions where it remains accessible (typically through compounding pharmacies under licensed prescribers). Purchase and self-administration outside of a licensed prescriber relationship is subject to regulatory restrictions.
Sermorelin and other GHRH analogues are prohibited in sport at all times by WADA under the S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics category. Athletes subject to drug testing must be aware of this classification.
Reported adverse events in clinical trials include injection-site reactions (pain, swelling, redness, itching), headache, flushing, dysgeusia (altered taste), and rare hypersensitivity reactions. Theoretical risks include pituitary axis effects with prolonged use.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.